F-Seven Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 4.50 M
as on 16-11-2024
- Paid Up Capital ₹ 4.11 M
as on 16-11-2024
- Company Age 28 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 13.36%
(FY 2023)
- Profit 13.93%
(FY 2023)
- Ebitda 6.24%
(FY 2023)
- Net Worth 3.18%
(FY 2023)
- Total Assets 3.25%
(FY 2023)
About F-Seven Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 M and a paid-up capital of Rs 4.11 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Aggarwal, Mayank Aggarwal, and Nitin Aggarwal serve as directors at the Company.
- CIN/LLPIN
U33112DL1996PTC076314
- Company No.
076314
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Feb 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at F-Seven Pharmaceutical?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Aggarwal  | Director | 20-Jan-2014 | Current |
| Mayank Aggarwal | Director | 20-Jan-2014 | Current |
| Nitin Aggarwal | Director | 27-Jun-2024 | Current |
Financial Performance of F-Seven Pharmaceutical.
F-Seven Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.36% increase. The company also saw a substantial improvement in profitability, with a 13.93% increase in profit. The company's net worth moved up by a moderate rise of 3.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of F-Seven Pharmaceutical?
In 2023, F-Seven Pharmaceutical had a promoter holding of 65.73% and a public holding of 34.27%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Unity Automobiles Private LimitedActive 13 years 4 monthsSuresh Aggarwal and Mayank Aggarwal are mutual person
- Mv Promoters Private LimitedActive 12 years 4 months
Suresh Aggarwal and Nitin Aggarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at F-Seven Pharmaceutical?
Unlock and access historical data on people associated with F-Seven Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of F-Seven Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped F-Seven Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
